e-learning
resources
Glasgow 2004
Wednesday 08.09.2004
Sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis
O. Baranova, T. Kotenko, O. Baklanova (St Petersburg, Russia)
Source:
Annual Congress 2004 - Sarcoidosis
Session:
Sarcoidosis
Session type:
Poster Discussion
Number:
4373
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Baranova, T. Kotenko, O. Baklanova (St Petersburg, Russia). The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis. Eur Respir J 2004; 24: Suppl. 48, 4373
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 85s
Year: 2007
The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 434s
Year: 2002
The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007
Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020
Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Contemporary surgical issues in NSCLC treatment
Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Year: 2007
Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Long-term treatment with clarithromycin of stage II COPD patients with frequent exacerbations
Source: Annual Congress 2008 - Management of COPD
Year: 2008
The use test valsalva manoevre (VM) in diagnosis pulmonary hypertension (PH) for early rehabilitation of patients with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 72s
Year: 2006
Phase 2B dose selection of BG00011 for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Year: 2018
The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018
Year: 2019
Stage IV sarcoidosis: comparison of survival with the general population and causes of death
Source: Eur Respir J 2011; 38: 1368-1373
Year: 2011
Disease severity for enrollment criteria of patients with idiopathic pulmonary fibrosis (IPF) in clinical trial: evaluation of time to first episode of acute exacerbation (TTA)
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia
Source: International Congress 2017 – Clinical problems in lung diseases
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept